


**Product Name** : Lapatinib  
**Cat. No.** : PC-45894  
**CAS No.** : 231277-92-2  
**Molecular Formula** : C<sub>29</sub>H<sub>26</sub>ClFN<sub>4</sub>O<sub>4</sub>S  
**Molecular Weight** : 581.0576  
**Target** : EGFR  
**Solubility** : DMSO: ≥ 39 mg/mL



## Biological Activity

Lapatinib (GW 572016) is a reversible, selective dual tyrosine kinase inhibitor of both **EGFR** and **ErbB2** with IC<sub>50</sub> of 10.8 and 9.2 nM in cell-free assays, respectively.

Lapatinib (GW 572016) displays no significant activity against other kinases, including ErbB4, c-Src, and c-Raf1.

Lapatinib (GW 572016) reduces tyrosine phosphorylation of EGFR and erbB2, and inhibits activation of Erk1/2 and AKT both in vitro and in vivo.

Lapatinib (GW 572016) inhibits tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg; orally active.

## References

Xia W, et al. *Oncogene*. 2002 Sep 12;21(41):6255-63.

Rusnak DW, et al. *Mol Cancer Ther*. 2001 Dec;1(2):85-94.

Konecny GE, et al. *Cancer Res*. 2006 Feb 1;66(3):1630-9.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com